Julphar pares losses with revenue hike

Julphar pares losses with revenue hike

Gulf Pharmaceutical Industries, the drug maker known as Julphar, attributed a 93 per cent increase in revenue in 2020 to "successful market strategies" in neighbouring markets, helping it to pare losses as it continues to implement a strategy to turn around its performance.

Revenue grew to Dh581.2 million as temporary import bans that had been in place in Saudi Arabia, Bahrain, Oman and Kuwait were lifted, meaning losses for the year were reduced by 42 per cent Dh293.2m, according to documents filed at Abu Dhabi Securities Exchange, where its share is traded.



“Our results demonstrate our effective approach that is flourishing on a